Vera Therapeutics, Inc. (VERA) Balance Sheet

The balance sheet is weakening as retained earnings deficits expanded by $530M over six quarters, reflecting the escalating Phase 3 ORIGIN trial costs. This trajectory suggests the company is consuming equity at an accelerating pace, with quarterly equity drawdowns averaging roughly $28M in 2026, which may indicate a need for external capital before the next major milestone.

The debt level is modest relative to assets, but the D/E ratio is climbing because equity is shrinking faster than debt is being repaid. This suggests the company is relying on a fixed debt facility while burning through equity, and with no revenue, the debt service appears to be funded by cash reserves, which may constrain future flexibility.

The asset base is dominated by cash and short-term investments rather than fixed assets, with PPE representing less than 0.5% of total assets. This confirms the business model relies on outsourced manufacturing and CROs, not internal infrastructure, which means the balance sheet offers little collateral for additional borrowing, reinforcing the likelihood of equity financing.

The equity base is being eroded by operating losses that outpace any capital raises, with the retained deficit now exceeding total equity. This suggests that the company's book value is increasingly dependent on future financing rather than organic accumulation, and the negative ROE of -50.7% indicates that shareholder capital is being consumed at a rate that may not be sustainable without a successful clinical outcome.

The current ratio appears strong, but the dramatic cash decline over two quarters suggests the company is deploying capital rapidly into the Phase 3 program. With quarterly operating losses averaging $100M in 2026, the current cash position may cover less than one quarter of operations, implying that the company will likely need to raise funds imminently to maintain liquidity through the next clinical data readout.